Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.

Talhouk A, Kommoss S, Mackenzie R, Cheung M, Leung S, Chiu DS, Kalloger SE, Huntsman DG, Chen S, Intermaggio M, Gronwald J, Chan FC, Ramus SJ, Steidl C, Scott DW, Anglesio MS.

PLoS One. 2016 Apr 20;11(4):e0153844. doi: 10.1371/journal.pone.0153844. eCollection 2016.

2.

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.

Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, Nostro C, Wang R, Muthuswamy LB, Crawford HC, Arrowsmith C, Kalloger SE, Renouf DJ, Connor AA, Cleary S, Schaeffer DF, Roehrl M, Tsao MS, Gallinger S, Keller G, Muthuswamy SK.

Nat Med. 2015 Nov;21(11):1364-71. doi: 10.1038/nm.3973. Epub 2015 Oct 26.

PMID:
26501191
3.

Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups.

Leo JM, Kalloger SE, Peixoto RD, Gale NS, Webber DL, Owen DA, Renouf D, Schaeffer DF.

J Clin Pathol. 2016 May;69(5):431-9. doi: 10.1136/jclinpath-2015-203337. Epub 2015 Oct 23.

PMID:
26500334
4.

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.

Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU.

Oncotarget. 2015 Nov 17;6(36):39088-97. doi: 10.18632/oncotarget.5142.

5.

Gastrointestinal Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy Specimens: Adequate Diagnostic Yield and Accuracy Can Be Achieved without On-Site Evaluation.

O'Connor K, Cheriyan DG, Li-Chang HH, Kalloger SE, Garrett J, Byrne MF, Weiss AA, Donnellan F, Schaeffer DF.

Acta Cytol. 2015;59(4):305-10. doi: 10.1159/000439398. Epub 2015 Sep 5.

PMID:
26339900
6.

Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.

Riazy M, Kalloger SE, Sheffield BS, Peixoto RD, Li-Chang HH, Scudamore CH, Renouf DJ, Schaeffer DF.

Mod Pathol. 2015 Oct;28(10):1383-9. doi: 10.1038/modpathol.2015.89. Epub 2015 Jul 31.

PMID:
26226846
7.

Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.

O'Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsch R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF.

Am J Surg Pathol. 2015 Apr;39(4):472-8. doi: 10.1097/PAS.0000000000000333.

PMID:
25634751
8.

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.

Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, Schaeffer DF.

Arch Pathol Lab Med. 2014 Nov;138(11):1495-502. doi: 10.5858/arpa.2013-0604-OA.

PMID:
25357111
9.

Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas.

Alsolami S, El-Bahrawy M, Kalloger SE, AlDaoud N, Pathak TB, Chung CT, Mulligan AM, Tomlinson IP, Pollard PJ, Gilks CB, McCluggage WG, Clarke BA.

Int J Gynecol Pathol. 2014 Nov;33(6):560-7. doi: 10.1097/PGP.0000000000000091. Erratum in: Int J Gynecol Pathol. 2015 Mar;34(2):213. Cheung, Catherine T [corrected to Chung, Catherine T].

PMID:
25272294
10.

Determinants of quality of life in ovarian cancer survivors: a pilot study.

Teng FF, Kalloger SE, Brotto L, McAlpine JN.

J Obstet Gynaecol Can. 2014 Aug;36(8):708-15.

PMID:
25222166
11.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
12.

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF.

Hum Pathol. 2014 Jun;45(6):1258-68. doi: 10.1016/j.humpath.2014.02.006. Epub 2014 Feb 20.

PMID:
24767857
13.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

14.

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.

Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ.

PLoS One. 2013 Dec 23;8(12):e82406. doi: 10.1371/journal.pone.0082406. eCollection 2013.

15.

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 27;8(9). doi: 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a. eCollection 2013.

16.

Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.

Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB.

Int J Gynecol Pathol. 2013 Nov;32(6):529-35. doi: 10.1097/PGP.0b013e31827630eb.

PMID:
24071867
17.

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.

Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J.

Histopathology. 2013 Nov;63(5):704-12. doi: 10.1111/his.12219. Epub 2013 Sep 2.

PMID:
24033430
18.

Type-specific cell line models for type-specific ovarian cancer research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4. PLoS One. 2013;8(9). doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a.

19.

Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL; Ovarian Tumor Tissue Analysis consortium.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23.

20.

Reproducibility of histological cell type in high-grade endometrial carcinoma.

Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE, Köbel M.

Mod Pathol. 2013 Dec;26(12):1594-604. doi: 10.1038/modpathol.2013.102. Epub 2013 Jun 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk